Global Microbiome Therapeutics Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Microbiome Therapeutics market size will reach 261.68 Million USD in 2025 and is projected to reach 3,052.43 Million USD by 2032, with a CAGR of 42.04% (2025-2032). Notably, the China Microbiome Therapeutics market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Microbiome therapeutics, also known as microbiota-based therapies, are treatments or interventions that aim to modify the composition or function of the microbiome to improve health outcomes. The microbiome refers to the collection of microorganisms (such as bacteria, viruses, fungi, and archaea) that inhabit the human body, particularly the gut, and play important roles in digestion, immunity, metabolism, and overall well-being. Microbiome therapeutics can include a range of approaches, such as probiotics (live beneficial microorganisms), prebiotics (substances that promote the growth of beneficial microorganisms), postbiotics (metabolites or byproducts of microbial activity), fecal microbiota transplantation (transferring fecal material containing a healthy microbiome into a recipient.
The major global suppliers of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, AOBiome, C3 Jian, Rebiotix, MicroBiome Therapeutics, Metabiomics, Ritter Pharmaceuticals, Symberix, Azitra, OpenBiome, Osel, Symbiotix Biotherapies, Metabogen, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Microbiome Therapeutics. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Microbiome Therapeutics market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Microbiome Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Microbiome Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Microbiome Therapeutics Include:
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics
Metabiomics
Ritter Pharmaceuticals
Symberix
Azitra
OpenBiome
Osel
Symbiotix Biotherapies
Metabogen
Microbiome Therapeutics Product Segment Include:
Upper GIT
Lower GIT
Microbiome Therapeutics Product Application Include:
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Microbiome Therapeutics Industry PESTEL Analysis
Chapter 3: Global Microbiome Therapeutics Industry Porter's Five Forces Analysis
Chapter 4: Global Microbiome Therapeutics Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Microbiome Therapeutics Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Microbiome Therapeutics Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Microbiome Therapeutics Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Microbiome Therapeutics market size will reach 261.68 Million USD in 2025 and is projected to reach 3,052.43 Million USD by 2032, with a CAGR of 42.04% (2025-2032). Notably, the China Microbiome Therapeutics market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Microbiome therapeutics, also known as microbiota-based therapies, are treatments or interventions that aim to modify the composition or function of the microbiome to improve health outcomes. The microbiome refers to the collection of microorganisms (such as bacteria, viruses, fungi, and archaea) that inhabit the human body, particularly the gut, and play important roles in digestion, immunity, metabolism, and overall well-being. Microbiome therapeutics can include a range of approaches, such as probiotics (live beneficial microorganisms), prebiotics (substances that promote the growth of beneficial microorganisms), postbiotics (metabolites or byproducts of microbial activity), fecal microbiota transplantation (transferring fecal material containing a healthy microbiome into a recipient.
The major global suppliers of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, AOBiome, C3 Jian, Rebiotix, MicroBiome Therapeutics, Metabiomics, Ritter Pharmaceuticals, Symberix, Azitra, OpenBiome, Osel, Symbiotix Biotherapies, Metabogen, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Microbiome Therapeutics. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Microbiome Therapeutics market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Microbiome Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Microbiome Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Microbiome Therapeutics Include:
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics
Metabiomics
Ritter Pharmaceuticals
Symberix
Azitra
OpenBiome
Osel
Symbiotix Biotherapies
Metabogen
Microbiome Therapeutics Product Segment Include:
Upper GIT
Lower GIT
Microbiome Therapeutics Product Application Include:
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Microbiome Therapeutics Industry PESTEL Analysis
Chapter 3: Global Microbiome Therapeutics Industry Porter's Five Forces Analysis
Chapter 4: Global Microbiome Therapeutics Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Microbiome Therapeutics Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Microbiome Therapeutics Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Microbiome Therapeutics Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Microbiome Therapeutics Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Microbiome Therapeutics Product by Type
- 1.2.1 Upper GIT
- 1.2.2 Lower GIT
- 1.3 Microbiome Therapeutics Product by Application
- 1.3.1 C. difficile Infection (CDI)
- 1.3.2 Inflammatory Bowel Disease (IBD)
- 1.3.3 Orphan Drug
- 1.3.4 Immuno-oncology
- 1.3.5 Others
- 1.4 Global Microbiome Therapeutics Market Size Analysis (2020-2032)
- 1.5 Microbiome Therapeutics Market Development Status and Trends
- 1.5.1 Microbiome Therapeutics Industry Development Status Analysis
- 1.5.2 Microbiome Therapeutics Industry Development Trends Analysis
- 2 Microbiome Therapeutics Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Microbiome Therapeutics Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Microbiome Therapeutics Market Analysis by Country
- 4.1 Global Microbiome Therapeutics Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Microbiome Therapeutics Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Microbiome Therapeutics Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.5 China Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.6 France Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.14 India Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Microbiome Therapeutics Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Microbiome Therapeutics Market Revenue by Key Suppliers (2021-2025)
- 5.2 Microbiome Therapeutics Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Microbiome Therapeutics Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Microbiome Therapeutics Market Analysis by Type
- 6.1 Global Microbiome Therapeutics Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Microbiome Therapeutics Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Seres Therapeutics
- 7.1.1 Seres Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Seres Therapeutics Microbiome Therapeutics Product Portfolio
- 7.1.3 Seres Therapeutics Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Assembly Biosciences
- 7.2.1 Assembly Biosciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Assembly Biosciences Microbiome Therapeutics Product Portfolio
- 7.2.3 Assembly Biosciences Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Synthetic Biologics
- 7.3.1 Synthetic Biologics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Synthetic Biologics Microbiome Therapeutics Product Portfolio
- 7.3.3 Synthetic Biologics Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Interxon
- 7.4.1 Interxon Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Interxon Microbiome Therapeutics Product Portfolio
- 7.4.3 Interxon Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 PureTech
- 7.5.1 PureTech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 PureTech Microbiome Therapeutics Product Portfolio
- 7.5.3 PureTech Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Synlogic
- 7.6.1 Synlogic Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Synlogic Microbiome Therapeutics Product Portfolio
- 7.6.3 Synlogic Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Enterome BioScience
- 7.7.1 Enterome BioScience Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Enterome BioScience Microbiome Therapeutics Product Portfolio
- 7.7.3 Enterome BioScience Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 4D Pharma
- 7.8.1 4D Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 4D Pharma Microbiome Therapeutics Product Portfolio
- 7.8.3 4D Pharma Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Second Genome
- 7.9.1 Second Genome Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Second Genome Microbiome Therapeutics Product Portfolio
- 7.9.3 Second Genome Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 AOBiome
- 7.10.1 AOBiome Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 AOBiome Microbiome Therapeutics Product Portfolio
- 7.10.3 AOBiome Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 C3 Jian
- 7.11.1 C3 Jian Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 C3 Jian Microbiome Therapeutics Product Portfolio
- 7.11.3 C3 Jian Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 Rebiotix
- 7.12.1 Rebiotix Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Rebiotix Microbiome Therapeutics Product Portfolio
- 7.12.3 Rebiotix Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.13 MicroBiome Therapeutics
- 7.13.1 MicroBiome Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 MicroBiome Therapeutics Microbiome Therapeutics Product Portfolio
- 7.13.3 MicroBiome Therapeutics Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.14 Metabiomics
- 7.14.1 Metabiomics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.14.2 Metabiomics Microbiome Therapeutics Product Portfolio
- 7.14.3 Metabiomics Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.15 Ritter Pharmaceuticals
- 7.15.1 Ritter Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.15.2 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
- 7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.16 Symberix
- 7.16.1 Symberix Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.16.2 Symberix Microbiome Therapeutics Product Portfolio
- 7.16.3 Symberix Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.17 Azitra
- 7.17.1 Azitra Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.17.2 Azitra Microbiome Therapeutics Product Portfolio
- 7.17.3 Azitra Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.18 OpenBiome
- 7.18.1 OpenBiome Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.18.2 OpenBiome Microbiome Therapeutics Product Portfolio
- 7.18.3 OpenBiome Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.19 Osel
- 7.19.1 Osel Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.19.2 Osel Microbiome Therapeutics Product Portfolio
- 7.19.3 Osel Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.20 Symbiotix Biotherapies
- 7.20.1 Symbiotix Biotherapies Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.20.2 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
- 7.20.3 Symbiotix Biotherapies Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.21 Metabogen
- 7.21.1 Metabogen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.21.2 Metabogen Microbiome Therapeutics Product Portfolio
- 7.21.3 Metabogen Microbiome Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Microbiome Therapeutics Industry Chain Analysis
- 8.2 Microbiome Therapeutics Product Downstream Application Analysis
- 8.2.1 Global Microbiome Therapeutics Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Microbiome Therapeutics Revenue and Forecast by Application (2020-2032)
- 8.3 Microbiome Therapeutics Typical Downstream Customers
- 8.4 Microbiome Therapeutics Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
